0001415889-24-010139.txt : 20240403
0001415889-24-010139.hdr.sgml : 20240403
20240403180017
ACCESSION NUMBER: 0001415889-24-010139
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Verwijs Marinus
CENTRAL INDEX KEY: 0001916553
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 24820530
MAIL ADDRESS:
STREET 1: C/O AEROVATE THERAPEUTICS, INC.
STREET 2: 200 BERKELEY STREET, FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-04032024_060410.xml
X0508
4
2024-04-01
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001916553
Verwijs Marinus
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
CHIEF TECHNICAL OFFICER
1
Common Stock
2024-04-01
4
M
0
5300
14.59
A
5300
D
Common Stock
2024-04-01
4
S
0
3796
28.8669
D
1504
D
Common Stock
2024-04-01
4
S
0
1504
29.999
D
0
D
Stock Option (Right to Buy)
14.59
2024-04-01
4
M
0
5300
0
D
2032-03-20
Common Stock
5300
79400
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.475 to $29.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.65 to $30.45, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.
/s/ George A Eldridge, Attorney-in-Fact
2024-04-03